How did the Polynovo (ASX:PNV) share price respond last earnings season?

The medical device company delivers its full 2021 financial year results tomorrow.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Polynovo Ltd (ASX: PNV) share price is up 1.9% in late afternoon trading to $2.13 per share.

The S&P/ASX 200 Index (ASX: XJO), meanwhile, is struggling to hold on to its earlier gains, though currently still up 0.2%.

Polynovo is under the microscope today as the ASX medical device developer gets set to deliver its full year 2021 financial results (FY21) tomorrow.

With investors keenly awaiting Thursday's results, we look back to how the Polynovo share price moved following the release of its FY20 results.

A doctor looks unsure.

Image source: Getty images

What did Polynovo report in FY20?

The Polynovo share price fell 6.5% on 26 August 2020, the day the company reported its FY20 results.

The fall came despite a 104% increase in sales revenue reported over the year, to $19.1 million. Revenue grew across the company's markets, with particularly strong growth in the United States.

Likely contributing to Polynovo shares falling after last year's results was the 28.8% year-on-year increase in operating expenses which reached $22.6 million. The company reported an operating loss of $1.1 million and a net loss after tax of $4.2 million.

Polynovo finished off FY20 with a cash balance of $11.6 million.

No guidance was offered for FY21. However, management said at the time they planned to reinvest funds back into the business for new product development and to expand into new markets.

Polynovo share price snapshot

Over the past 12 months, Polynovo's share price is down 10%. By comparison the ASX 200 is up 22% since this time last year.

Year-to-date, the Polynovo has yet to recover from the sharp falls it suffered in January. Its shares are down 45% in 2021.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man with a perplexed expression on his face scratches his head.
Healthcare Shares

4DMedical shares are up 670% — but why have they halved?

Can the company turn its commercial momentum into another explosive share-price rebound?

Read more »

Businesswoman with a pleased smile reading on her laptop at a desk in the office with a look of satisfaction.
Healthcare Shares

Are CSL shares dirt cheap and a strong buy?

There is plenty for CSL to prove next week. The current valuation is why I am still interested.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Why this ASX healthcare stock is a top rebound candidate with big upside 

This could be a perfect buy-low candidate.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

2 ASX healthcare stocks tipped to return 34% to 63%

These companies could be poised for much bigger things.

Read more »

Smiling couple looking at a phone at a bargain opportunity.
ASX Share Market News

Are Pro Medicus shares now too cheap to ignore?

The discount looks tempting, but slowing growth could expose valuation risks.

Read more »

Two ASX share investors sharing a secret.
Healthcare Shares

Cochlear shares are quietly rebounding: Is a bigger rally coming?

After a 58% plunge, Cochlear doesn’t need perfection to surprise investors.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech is tipped to more than double in value

Encouraging trial results have the analysts excited.

Read more »

person climbing mountain
Healthcare Shares

CSL share price forecast: How high could it climb in the next year?

CSL shares could roar back, but investors need more than hope.

Read more »